0001193125-24-075426.txt : 20240322 0001193125-24-075426.hdr.sgml : 20240322 20240322170639 ACCESSION NUMBER: 0001193125-24-075426 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240322 DATE AS OF CHANGE: 20240322 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IO Biotech, Inc. CENTRAL INDEX KEY: 0001865494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870909276 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41008 FILM NUMBER: 24776126 BUSINESS ADDRESS: STREET 1: OLE MAALOES VEH 3 CITY: COPENHAGEN STATE: G7 ZIP: 2200 BUSINESS PHONE: 4570702980 MAIL ADDRESS: STREET 1: OLE MAALOES VEH 3 CITY: COPENHAGEN STATE: G7 ZIP: 2200 10-K/A 1 d795877d10ka.htm 10-K/A 10-K/A
trueFY0001865494DE 0001865494 2023-01-01 2023-12-31 0001865494 2023-06-30 0001865494 2024-02-28 iso4217:USD xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-K/A
(Amendment No. 1)
 
 
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
OR
 
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM
    
TO
    
Commission File Number
001-41008
 
 
IO BIOTECH, INC.
(Exact name of Registrant as specified in its Charter)
 
 
 
Delaware
  
87-0909276
(State or other jurisdiction of
incorporation or organization)
  
(I.R.S. Employer
Identification No.)
Ole Maaløes Vej 3
DK-2200 
Copenhagen
N
Denmark
  
NA
(Address of principal executive offices)
  
(Zip Code)
Registrant’s telephone number, including area code: +45 7070 2980
Securities registered pursuant to Section 12(b) of the Act:
 
 
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common stock, par value $0.001 per share
  
IOBT
  
The Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act: None
 
 
Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer   ☐    Accelerated filer   ☐
Non-accelerated
filer		   ☒    Smaller reporting company   ☒
     Emerging growth company   ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to
§240.10D-1(b). ☐
Indicate by check mark whether the Registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act). Yes ☐ No ☒
As of June 30, 2023, the last day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the Common Stock held by
non-affiliates
of the registrant was approximately $31.1 million.
The number of shares of Registrant’s Common Stock, par value $0.001 per share, outstanding as of February 28, 2024 was 65,880,914.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s proxy statement relating to its 2024 Annual Meeting of Stockholders have been incorporated by reference herein in response to Part III, as specifically set forth in Part III.
 
 
 
EXPLANATORY NOTE
This Amendment No. 1 on Form
10-K/A
(the “Amendment”) of IO Biotech, Inc. (the “Company”) amends the Company’s Annual Report on Form
10-K
for the year ended December 31, 2023, originally filed with the Securities and Exchange Commission on March 5, 2024 (the “Original Report”). This Amendment is being filed solely for the purpose of inserting the conformed signature of the current Principal Accounting Officer, which was inadvertently omitted from the Original Report.
This Amendment speaks as of the original filing date of the Form
10-K,
does not reflect events that may have occurred after the filing date of the Original Report, and does not modify or update in any way the Company’s financial statements or any other disclosures made in the Original Report. No other changes have been made to the Original Report.
As required by Rule
12b-15
of the Securities Exchange Act of 1934, as amended, this Amendment contains new certifications by the Company’s principal executive officer and principal financial officer, which are being filed as exhibits to the Amendment. Because the Amendment includes no financial statements, the Company is not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
EXHIBITS INDEX
 
Exhibit

Number
   
Description
31.1+    Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2+    Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
101.INS    Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH    Inline XBRL Taxonomy Extension Schema Document
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
*
Previously filed.
+
Filed herewith.
†
Indicates a management contract or compensatory plan or arrangement.
#
Portions of the exhibit have been or will be excluded because it is both not material and is the type of information that the registrant treats as private or confidential.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized
.
 
   
IO Biotech, Inc.
Date: March 22, 2024     By:  
/s/
Mai-Britt
Zocca
     
Mai-Britt
Zocca, Ph.D.
     
Chief Executive Officer and Director
(Principal Executive Officer)
Pursuant to the requirements of the
Securities
Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
 
Name
   
Title
   
Date
/s/
Mai-Britt
Zocca, Ph.D.
Mai-Britt
Zocca, Ph.D.
   
Chief Executive Officer and Director
(Principal Executive Officer)
    March 22, 2024
/s/ Amy Sullivan, M.B.A.
Amy Sullivan, M.B.A.
   
Chief Financial Officer
(Principal Financial Officer)
    March 22, 2024
/s/ Brian Burkavage
Brian Burkavage
   
Vice President of Finance
(Principal Accounting Officer)
    March 22, 2024
/s/ Peter Hirth, Ph.D.*
    Chairman of the Board    March 5, 2024
Peter Hirth, Ph.D.
      
/s/ Kathleen Sereda Glaub, M.B.A.*
    Director    March 5, 2024
Kathleen Sereda Glaub, M.B.A.
      
/s/ Christian Elling, Ph.D.*
    Director    March 5, 2024
Christian Elling, Ph.D.
      
/s/ Helen Collins, MD*
    Director    March 5, 2024
Helen Collins, MD
      
/s/ Jack B. Nielsen*
    Director    March 5, 2024
Jack B. Nielsen
      
/s/ Heidi Hunter*
    Director    March 5, 2024
Heidi Hunter
      
/s/ David V. Smith, M.B.A.*
    Director    March 5, 2024
David Smith, M.B.A.
      
* Previously signed.
EX-31.1 2 d795877dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mai-Britt Zocca, certify that:

1. I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K of IO Biotech, Inc.; and

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Date: March 22, 2024     By:   /s/ Mai-Britt Zocca
     

Mai-Britt Zocca, Ph.D.

Chief Executive Officer and Director

      (Principal Executive Officer)
 EX-31.2 3 d795877dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Amy Sullivan, certify that:

1. I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K of IO Biotech, Inc.; and

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Date: March 22, 2024     By:   /s/ Amy Sullivan, M.B.A.
     

Amy Sullivan, M.B.A.

Chief Financial Officer

      (Principal Financial Officer)
 EX-101.SCH 4 iobt-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 5 iobt-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 6 iobt-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 iobt-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 8 iobt-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Feb. 28, 2024
Jun. 30, 2023
Document Information [Line Items]      
Document Type 10-K/A    
Amendment Flag true    
Document Period End Date Dec. 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --12-31    
Entity Registrant Name IO BIOTECH, INC.    
Entity Central Index Key 0001865494    
Entity File Number 001-41008    
Entity Tax Identification Number 87-0909276    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One Ole Maaløes Vej 3    
Entity Address, City or Town Copenhagen N    
Entity Address, Country DK    
Entity Address, Postal Zip Code DK-2200    
City Area Code +45    
Local Phone Number 7070 2980    
Title of 12(b) Security Common stock, par value $0.001 per share    
Trading Symbol IOBT    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 31.1
Entity Common Stock, Shares Outstanding   65,880,914  
Document Annual Report true    
Document Transition Report false    
Documents Incorporated by Reference [Text Block] Portions of the registrant’s proxy statement relating to its 2024 Annual Meeting of Stockholders have been incorporated by reference herein in response to Part III, as specifically set forth in Part III.    
Amendment Description This Amendment No. 1 on Form 10-K/A (the “Amendment”) of IO Biotech, Inc. (the “Company”) amends the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, originally filed with the Securities and Exchange Commission on March 5, 2024 (the “Original Report”). This Amendment is being filed solely for the purpose of inserting the conformed signature of the current Principal Accounting Officer, which was inadvertently omitted from the Original Report. This Amendment speaks as of the original filing date of the Form 10-K, does not reflect events that may have occurred after the filing date of the Original Report, and does not modify or update in any way the Company’s financial statements or any other disclosures made in the Original Report. No other changes have been made to the Original Report. As required by Rule 12b-15 of the Securities Exchange Act of 1934, as amended, this Amendment contains new certifications by the Company’s principal executive officer and principal financial officer, which are being filed as exhibits to the Amendment. Because the Amendment includes no financial statements, the Company is not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.    
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 3 37 1 false 0 0 false 2 false false R1.htm 1001 - Document - Cover Page Sheet http://www.iobiotech.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports [dq-0540-DocumentPeriodEndDate-Value] In submission type 10-K/A, DocumentPeriodEndDate value 2023-12-31, is not equivalent to header element periodOfReport value, 03-19-2024, in the Required Context. d795877d10ka.htm 11 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode - d795877d10ka.htm 7 d795877d10ka.htm iobt-20231231.xsd iobt-20231231_cal.xml iobt-20231231_def.xml iobt-20231231_lab.xml iobt-20231231_pre.xml http://xbrl.sec.gov/dei/2023 true true JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d795877d10ka.htm": { "nsprefix": "iobt", "nsuri": "http://www.iobiotech.com/20231231", "dts": { "inline": { "local": [ "d795877d10ka.htm" ] }, "schema": { "local": [ "iobt-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "iobt-20231231_cal.xml" ] }, "definitionLink": { "local": [ "iobt-20231231_def.xml" ] }, "labelLink": { "local": [ "iobt-20231231_lab.xml" ] }, "presentationLink": { "local": [ "iobt-20231231_pre.xml" ] } }, "keyStandard": 37, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 3, "entityCount": 1, "segmentCount": 0, "elementCount": 44, "unitCount": 2, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 37 }, "report": { "R1": { "role": "http://www.iobiotech.com/role/CoverPage", "longName": "1001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d795877d10ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d795877d10ka.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r4", "r5", "r6" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r4", "r5", "r6", "r8" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r11" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r9" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r10" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r4", "r5", "r6" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r3" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.iobiotech.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 19 0001193125-24-075426-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-075426-xbrl.zip M4$L#!!0 ( -*(=EA-'W4YP1@ ,'& 0 9#T=:W<:-_9[?X4.V;9VUSP&L TX80_&N&&3@ ^0;KI?>L2,,-,,(SHSV+"_ M?N^5-"_>8X--&GK2!)!&NM)]/Z1Y^Z_IR"(/S'%-;K_[6IH>>-*]GLX^-C!GXPNENENF_376?=IWK QW[J%GKI#%YCYUF=\=6PTS>"#:^2(K&X.N"T,_ M%D1?K5PN9T5KT-4UEW6$0;7LET\?N_J0C6C:M%V/VGH,%G,-[//]#38'N,OT MS#U_R$*#V!>_H^GR8EZ[7#>T[!&./':83CUFK'RFG*6.[G"+9 M,UL.G&J, :A/' ?(8-43JC7V")OJP^7=L276U::F[B[O*YIBG5U37]X5&N(= MO;&SHB>TQ+I.W/0]I>.@]X"Z?;&/JB'6>6JMP=.7CQ$JFWC.&O1 :P"JXRW. M#3_&B62Z:C -20_(FWVY[GP,NWO+^X==LYY#;7? G1'U@-UQMGPZET]K%U&* M7[?<>6Z%2=.PR[$G_%U?-Z]VGLZ5TH&06,W$*'=2*'\8-> ?S_0L5M5RZ0_9 MVMNL_/;#VQ'S*-&Y[3$;]L!C4R^+SUT1?4@=EWGO/O=NTZ44P4G2[*^)^? N M59?=T[W9F*6R,$A63='GQHRXWLQB[U*X@/20F?=#KV(C^-95G^I?[QU@&2.M MAZ;&K5/6M83[XSQFF.[;HK$)L;C-H,J<5')TY\J-I&,P6'Z&]-1DQ MQ]2)34?X)#,KM1&S#?C?N[7H?4HN;.IUV.!=ZBZG_0%_D$QZ7,O_49"?4\0$ MP6!.']+GY_E4U7,F[&TV-OSJV6ZX/A&3F:Y.K3MHY<8M_.8FGKF0JM[^OO6\ M#1O0-ZO#S ZUFK;!IA_8+/&+!<3SMT$/>>,N2.(LNN!P*Q+ M45CG!I.32%1IN8O"93%?N-@.O.I-8P&2;!SO#ALP%*',K;Y%GJJX0@/!L$3H MK8H'9/DNY9JCL87,)GX;.C@KJM^TKV0S4]< ZA7#1\<47UT^<<0WH<;'^+HF'\8QLLN'7\LR"[X"FK5\6X M(56$*IW3X(__9-@6PFJ$?;4\B)5P%D/US,[-DXWMR=(MJKEM.W?Q1R%W4%LC M;0Y/;S$-N5*/\.'/SYW;\(E MCAAU)PZK*I.K HW^('Y3,"H.LWQ(%U0-L%+*G)OV5:2KQ0;>U8@Z M]Z:=QL\50B<>]W]Q!%3BI]1*H,'=& =C>'Q=_J#L$ M%]?C]AFYR=0S))\#4;4$MKF)-]'J:OK8P&114KUX$JEF[ EZ\:6LPYS$B\O0&*W[S@ M[M*^Q8C.+&M,#1&22^52XCM2N_]= 7C=[MPT.NEZ^^/'VEVW4?$_K =CGMSD M3E?\_=1RN1_1__8F".9X)? MJ? !N[=@0J06B3!*T8NL+%&SB:%KMCVA5H>!@^=MR=@R0H',+:(:,#^W^M2R MN-?GTPC?EX094+XL7EPM,/Y3EO*49[*>$=OQQ!M-XDQ']BJ+?.]W/M5:/]-H$S(8>V@9:@;0[1#L_,4Y)^Y;TWC=(Q*((K(E: MO8?-6KE0C&P'_(6FLF":%V7=I5J*.\0;,C(0814R8]0A((:90392KHS!-*3O MFIQT*P8\EA[!4T,<.VW061JG3S,[2L/:&J58%P%>%1+Z'9[=*3!Q./*IZ@W3 MV:@//B5Z[G%^.MN\72&43PI;E<"UQY^6AFPBW]CJW9GQXK[J&6>HV5Z M&-DV,8"X'TU35)JF>-0T231-KU-K=9M"I>Q4VQ!P/D2_R 1WC4ZS?4-N.^VX M6R* ,IBN LR5"4A_1VSMPD[_]*:DE<^OEOZC7 D >V^#'ZH.K?/1R'0Q,TUN M31!10/JH)7;F^\DT XM1TZL.LXQS*FEBR"_2EN[@$2^I Z\-@QD)"4PK\M:PUA"HVTT'"3<%9R:LEH MNRVQS<[!KLNNLQ[D.OT9YCLK Z_TH\AQRADVF8@DT=I2"4P;10.)+@DGMTVE3)0EW8-T_4 MSY>I:NDRG2OGROG+B^4*>M[VV2F%E79 8(D4P4X"[">B%H)PAW!O"/;6GQ/' M= U31T2 8DBJJ[0]@&A&2S<$I,X]M^GK\4GKX"J9J:3Z69(8S2V^(PY MAX";..=BSN%T'9-%Y/$\M_A98E"3OF+0.:HY^UTJGUK>ZT#5Q"N8UQ/*UE*JVP1CY1*GUTYM\L70%0/[&_B1+@FD'8-_N6$FIG;OC MKD>M_YIC6366< ?+H.,_I//Y7&Y^RV)&Y%:0U.%CV^GQ1SLA&*@GDVY.G8^9 M/03>LI6CVWHNSK778P)5]_?$X)TJH,:Q8Z'M<@X-.!M6^765[;%+#:5,Z><; MYRQS)ETL+0OQ DD9= MH'K']$QXT!$X8PXSR'CBN!,,[WB<0 ^TUE1U2/ZD?XJ,@PG,FNY5CC&>OW., MI_2L$$^AN%6(9VEDIY#?07A(#O(">FH+NEH!_J(]]3Q_81]N6P\/TR#3,ZH/ MB6Y1U]V);GSRKAV>M]US*#+C(3C9W=D(FDYV9+_\C7#44MD+0<5X\I#:]^P0 M,,9M G( @ HU\%[-[)>*;J^RJY3-,=/R?2%:$MM5!9D AGUS/:Y_/2-CZI ' M:DT8^4<.2%0C8SR&,A3A\?V[5WO>+B5;)%\GWJLBYABO>W^#??#)IJ%8-T'* M==XO1^Y?=,K/08Z#6=NBKD'_(ETD+8*%M\PC'S_6U^S@0;E>R2WZ^[A%WT(? M[6C6OVH-.#"M;6"\!O?TU,Y#9@L@&6 M)3FB\L]=PWT%3%').K.0!Y^)A=^X-;$]ZHCZ)2=QV6OY\J!W_W'(1.XQCH(* M.=%.Y9X.@>!Q]PU"+2M 010W?:8ZP,B;T!'A#U_Q((JP693]&=!JWXNN>+<& M$_$L+4]$8;-+3F \T#[$G8!]YPXY%L80>2(5GJ'>/"4]4G>1C,3#:B&GP-"V M04[RD=7V09%!I_Z?L!9\2/2')Q$4-1A6I+H"$@$I=3U2SA&#SMS,=D2E"K]E M+2N:(Q[UDI=4ETNIZN]XW'4=<2F 6CQ._ ='8(M9L/T.M]$B MLF:$@74T(TW4,%07@>4;ZE%9KCA'C.$844$1E=0PZ<226=.DZ9ANNJ?R,"=( M,9=7^4(^$R@ D%Q U&-1KK5G4I:K#(B3N:=;DEYD#W$+%24F)KWR-T]ZSIS6 MMV!*1JBN ^DY>*N/V%=4^?;27Q/3#NQ3.C*0HB,UG#L".@?('%\D $)&8VK/ MSE"( @@@='!+[LF]PQ^]H=^< 9G*Q'J$62)*Y$4R!E,%^=S5JE6)9NW*[[:Q MPVKX_(XH2%7G%;#Z/7W#*>D&@HN;SJMM4PHEJD4RN[:SO[$B0.UR!U'>\](. M!LGOHAQQ3^'FC?$:WTW_B)PCR2'"'?('P2+[2"M'CJ$D&3S9%+5Y9M__2IY0 MCG2Q3372KCN](KTE+IO9IF1%."UUP/0]?W+=A;P[1A"*KD:*AGJTRUQRX%NK M=>%B:&AOQ'FQ5S;K2I4I'PKTIORJ-.)^UK:!)@19#N(K?F MR/91#FPC![;)\2:CAP0C)J.SQG(S[U6(VH?E5P%*74*R:^+6MB#N%XA<@WLS M6.,28"W0NE";$_>YA:<-E@#&W,"QG+C2G8!=D^?HO>#HK>^?HM^*#%7C%1$=:G3IS!VNCVUV$S$"4^T<_(YT\6+I"[S%U@^=8JK#Y>J MTC-]"^@A0G8#TQG)L,H8 *#8"2A5Q/0- 3:=&*:G@-M(7DU]X-3P >[4PKU+ M<(OHU@16>%T"&Q W#-C"KCVIJFVE.(H2:D@@N)LJP,H7Y)4L!^&W?5&7@.'KP>3 M[H,*UEQ.\.I2!@6_P!,'O2&W.L2 3S01G HF# *9*(IT+F*[('&LF6M*06)C M,A$D2QHO03:$LF&V*T44!E.A2>0;@MFC5!*(K/DJ9,>-1F4=4'P/2%0!"$J] M12D[J5^C@L+%7$;+W:0UX(1,//CYVBG/%<%W$0%UA\RR?"N"G"Q)=>XX8G>Z M*3<7A(XWN30(^9.-OLK G#(#=M)R693OSE>:>R\A?6N"%?X]L540JI [(PCZ MF=A&"Y-.!EU'_B/N"N(&5@*1)PPVAH8>R!IN&_Z-27]-Q/ER.2J]OX>!D&I& MLE1#U@&I.529D*SE@!T7+/BD*/@ !3=,X\9IPXGG.^@8C,2I"6ABL(!_*!JX M%=D+@&.>".Z$VK^U.)U/9\Q=,4SP'EC1$MQ2"Y2NPT26^RZ5/@>7$'8&QKZ( MDXD]&:4-+NX#P;Y14KE(50M:)KA6R8=1^3B 8 N^+0M0[YQLL.A&G@G 7947 MXL:O&0@()(K/=65?9X1//&&YB^,%8KA;UG> K%^5FIE#LK:\4%%+X UI95 M'MVTZY\_-5J]+MYDT>[C]V!)UQ;@>$MYS !M>!<[7JH?14XI5;U#CT&EM5;(.A04L]"*0^5.A>6O M'!I!G/*J0O*),=$$HPDB''++0-M@2,%2$-E_,[(DE''!E>\@]1R&%W.@&>*. M 2:&,]R!""7-9O,LPGAB MHP6BQY\B\;L^ XRP"K4>Z /T"2)=9"&!7-7+-$!KTB6[ M\*+7B[_"N>+&E[N/M5:MU^[\3EKM7B#^-K[?XP9DBV..488DK'/(:X65R]Z5 MN@;3>]G-P1B=N07]E=SF5CBQO?THHCN#ZMJ#?) 2PDJV=(++T9-C]7)"JKHKD1O/X,\GZNA#.>BYLF.BN]!6PZO%^;N1(7.X,[%V M3$:;$ B08VBV!E5B$] H+I/NK='\HQQ)4HLNW))'2F:,C@S*\EE0$B]A &(4;@/ F5SW6QSP:A R\(1RT M,[=YLG PF&#$#7,PPZ#B9"R>,FT1G 5LY1=EL>[5#A%..BP,-WB^/X*#,<: MS ]Y+2"QQ=43DK:C=HQX#NR3UT)^+5*S!F;4DT,(VGG<3]Q01BK,,"&KF'$F MR_)""D3Y3X$#1;I"1S[TKU!Q_5#R/+)6GVMW!!6$[2%:>9P[,0X6%0Z8=YD. MS3[:I@I! 8@9+^*.CP6/K?6E?'; M6O*Y7#X@GW67/1TMM._.0GO?O&X*E_6F\>6[*\?;ON2ML+SDK9S[]HY8)SV1 MUI!B3]%&WUG"I^MO31&QK:>_\SK,E+!&.D_]U%S!1-& MA+)Q63XO75X:;%K0M,S0@\'J4>V'DCJTJ1N!4E!C] #N%G5]#)0$MUPK0/R41'X[ M4X&^1/778=%Y_H7I/+^1SF\#F_%(YTRYH%C#,9A@HE M!<^'P/AS9;X_?'?K[U\$WSTZY38?S8#MP:42L3KY_OB +ZWO2_N;=_KHDKO M#M:V@DM.MF6(T_65L-$,46DG&2+?0]-^/ !O\37>M_/+R[\Y)DD^6[XHYBZL MO1,!L#!^-$\MWPW>-MJ'AX"W6Q&MQ*PW\OT1:U61_=E\/.\0<.=7 &)I7UC0 M+0NS\04DJHI?%%9R+'^TJ+CCG3H.6MDR%/W=(_S-MX#J^0H9E5N(I(( KX^F M9>$%"6RJBJA]T]>4N4ON#64N"VC&$>YL^D%ZRL3DV), MTT8R0]Y.EJB,!@XD14?N><$ZL>?=:S.?D%RX]\288(4N,J,A\Y7JA(ZZT00V M"D^LR!="]=F06@,_5RE"&+*#&-EA$QN>$@,"8H?<@2TPDH78,_MYI]JAY&]6 M7J!0/-_%6Y2><4WO+J8_?[V7..WR[.J3APL\^D)JS= )DT[S55(O^**57?9Z M);*HXCN-*]$RJWQ>UEGM_,K,79-@]7I6V3V02=.$FT(@SZTUS[K9Q'4YGZB9 MO@:=IS*YY+]"OT4!6KRI,'1)Y(*VK)14 MGD=X$Z9T/OK,XH^^TS'@%GS#HL(Q.!\B[F#[?@E?O,]59@MTBC9^4(O-Y:^& M"%#Y)\2-[_T.M\(N7)#=O.Y#^]9KT?9;?R5?@7"L0UOYCI/CUBPMT0,I]_J& M4E)#X9MQ0.*FZ.L:&7NRK?=24;8WN_$PC,+M+;Y][.ZJP,=AA(Z.(B@00;71 MC'0GEF4^4/N,?,I<9VJ'(4K6 /;MBH2%>M07E0(+LQ^EP%$*""D .IC:Y'KB M?*4/]-DO-=N- %@.T[?(^[\!KY$[A[FB(D!<)2,X<>_['./^Q7/41_8_;/9_ ML43('<-3X.]-QQLJX_N7/9-&?4A-9T1M/W9VS:ECO 0AGJ^CPV_ES8B+^-HO MNG9^G;(<]"@'#DP.?*#>T,((>!?O.Z7D5XM.^K[QO6^1$#K&1RFPE118BZVC M0#@*A.<+A/K0,5T/[?"&A=?#O)!U?P3_"7(\U746^; M2!!^CY3_,$+JJ96,;>SD=$<($A@2HQ*P,&F3>]O VJQB%FM9Q_7]^ANPB5VG M3=K&EWNY!V-VF-GYYIMA9C&&\95O&D/7HKRS M40###IU;L"\'H1]&Y\KGH1>["HSC6]\]5V:,4S6C;)I)/2A$3F:*"<=':#^@ M7%)A&H[WJ5%>LE1F^A_M4\85(#,VY;@!G4BE=C-JU'(BIHRKLICKW;D\@\WZ MKI"RR->B2<&E6K*_J:YMUQ.2L]E*CUE.2PCH$J(B)^C)\KW+X%P1%4C%-&S3 M_9*Q.R:ABAB,CFT:G5$5\K<0:+T#0DAJ3FH, S>*O0MO8,5>&,#H.AI?6T$, MNC!V!]>1%WOHW+T9#*W@TCT^L@8QA!>@_=D_:3WR M\>]7R X=UA@L)QS%KO-5;A!MG:]^MU: @Z .C M2YJB8U:"E5.>XD]"4+1_XW?E_$P#6>!#"A;G"S*#B,X+(:'@<(%-Y@<*KJM^ M;&(M)N"%8+-"TB1K@<>3]AD0GCX7[V%2TVN#34H,$W'G*[A'=#.:3FEK';=8 M!Y46:,4+"0GN11A';"M8<"D6%$I))*VIP2@( L+Z9,C'A"0H$E#DV,:0JEKO MB0*G"2U+(E:52D[N:47I\='CIB4*4T2#/F=5::9?LN#%S?'X^L@1=*UJW^TX!.XRP+=7R#8:U1,71YUNCL:LW-\\F?K]*JO&& Z["%)F; M&Z?Q?'+Z#AM.)W:V3SYMVM$ZMBW&1G%O@Y?LOV74?ZW31]1XB7;B:XB;DRE5 M[P0E]RKC)4NI3AX*EL)/$O>=B!PL0!VNB,!J[/5:V&U[)[LH]_6;ROB^QNNL M[97^J@WV!U"G[/QJ4]\FY2T3\E^2?U#FW_20\Y2UG?;/GQ.U0YQ;,T8G MX'ZAR4(R'.7A9,+P&%$/5(<)[/:%:)#]7XNOJD5D^_U(,)ZP.4[T)Y1_6-.\ M[<'X5\V\>O<.?G:A?/,1MN[.G>I##H7U]]\_4$L#!!0 ( -*(=E@&5S<9 MP@, ) - 1 9##,Q,BYH=&WM5]MNHT@0?8^4?R@AS6I& M,KXFJUV"D<#@&"T!"^.9Y+$-;=.*:1"T[?%^_1;8Q!XGF8OBS;[L@S%=KLNI M4^7J;G44W#F:.K)T4[N\4 ,[<"S-NI=[G697;>V6*&_M%4 U//,!C-N!YWA^ M7_HRL@-+@DGPX%A]:4"YIKJFE_KI4W+!*Q M\D?SFG$)R)(M.#J@.R2#.EG8D;V*]GJ1!ILA/-4R[D@OU- ME@I0TU="LKS&;,0%EQJ"V#$UM MC"^.I/YGJ;@"!]R- YZ3D"(\_=:P) MJ$,/0=3EBIF@0DD[1.C\B=JX_DD]HJ53707?,GK*ZC;ZVFKFGY M$(PLF%B#J6\'-@:W[@$#I_]JX:3WS\^QUR1(<^ =WTQH%E M?E,;1%O5J]?NE@"K!'3?T%UK(GOWCO4 >^C==OM]6DNS&Z G6YBLEDNV)KP! M(J<)-L1D32&G:T8W-,*XK, 2)I1'^!'@ILW?^*S( M;CH@4OR5@L[YBBS!IUF:"T@Y#'%R_$07M>6_Z@9*YV![8+!4T#!N@,W#Y@T0 M'GTGW_/0W6V"00I,$V$C[8\(;DFC!6WL\\YW244IFO%40(C."..(;0LK+O(5 MA4(002MJ, N"B+#I&/(Q)R&*E2D(>:47ID\\" M91&BP9#+R=E @DKEI1$ MC"]@PT2,=2XR&HJZEAE"2Z/+BS!=HUT$LVU%!.QX:)[6XXCKLAPG?^1GQ9&T M7>M47LK-2C<<"P:6XTS&^L!V;_M26ZK68]TTZ_47VPQ&?:G3;G^0P/!\G#65 M?(]A)Y%Q/W/T\<12ZI?O5OZT3M$I.O[5_,.O+5]0><(JW //SR>3]C M=KD=,-:*)PY^9/^24>^M09]0X\,_RJ\F+B,+*L]R2AYEQ@L6486L4Q;!+Q+W M2D8F=J "=R3'=NQV&SA"NU?'*$_UZ\YX7>--UJ>;@K%5SNJO5;1.!O==TVCJ MS4,!WI/\_Y#H\Y;I?4\)+];O5X]OG7,<)V-&YS!D'.=[N55X\SG#@T -YO^F M>E-3(<$?QSE#:C/D]AG+GW8T'P8G?I4;5>6]A1<@E.^O0[N1VBJO5"BL;F+_ M %!+ P04 " #2B'98;D$0):4# <$@ $0 &EO8G0M,C R,S$R,S$N M>'-DS5=1;]LV$'X?T/_ ZEVF9;=#;<0INF49 B3=D&U%@&$8:(JVBOKN_13="&R(H0U>25ELF M#$K1QIARCO'CX^,H7W&A95$9(- C*K<8[)_VA.A^.AK#%E:327I'%-VDD_'D M#?H]&\\GV?S-^ _TSX>[?]/42M!TP[8$&:+6S'PD6Z9+0MDBZ9!QN>32,+IQ M1!!JFL$/4BJ8578MU?:*K4A5F$7R=T4*ON(L3Q#40.@Y.)NH: X>(!^G(ZG6 M !EG^.'N]A>GU,=MCEWP6[PWMBJ.Q'VX[8BH=+HFI&S@*Z*7#EH;7.$\F,I*&/442M", MCM;R,ZZ-H4.E%!S((8_:&KCDC/>CP1 V8YN^I'6$D %X53W8YTI &M.^Z%@ M"(!0(?-4,MU;.V<)XYI2#00&RT$-2L6HO:R#KW&&X;XI63!@I29EN[(@@ABI MGJYAWW J\UP=/ R%*3.42&,*Y1EUX!"H S.V9NLS3L=9.LD2VP&($-(0VTG< MKBRY6$F[M)=B;G/Y%;R07?QV?W/D+KNTOY?0]WXF:[@>',K4;IN(.8/FQ1U? M!E<;.E6GQSD\L@X7^!#M U2:Y3^)2[>&%Z+!T\FW]Z?VJB%]'FW .#PE!:V* M80(X9YM%%LM$MLC4]\)_X241O!"/<1& M/M(U7-$/JU 3^Q#UD3S>_B"(+)DR'$Y5VSWQ%T@(*GYJ0N%+^KK2*P?+^3:&;6 2Z:/37ERO#V:% MT?Z).Y31R?;/-DK:,[GTZ-KLH*M[9 9=X<+I0(O>Y%GMGED MW[Y(0F0+Z=";%U,?GYUCY72C_- &.5'=P$=.U''P<+N(/@Q#GRDOZ*PNS.D" M#C\OXA3X[Y<]>Q/C+/H7$I]U__J^CP85_)^GV^N.!KR/=/D?4$L#!!0 ( M -*(=EB382[58@$ *@" 5 :6]B="TR,#(S,3(S,5]C86PN>&ULC5'= M2\,P$'\7_!]B?$[3CSVXLFZH0QET(A5E(#ZTZ74-MLEH4E<1_W>3SLHFBK[E M[GY?=YG,NKI"+] H+D6$/Z(&=X-CT^FIP0<@T"FE1#CK)7 M-+]:W*#511*CA5 Z%0S07+*V!J$10:76FY#2[7;KY 472E:M-@;*8;*F9OZP M,T1)X+BF-"_?)\NT827Q77^$'CTW]+UPY#ZAM_/E.R$V0L7% M,^FRIG)DLZ:^ZP9T .(=,NP4/T!O@P'KT=4ROF,EU"GAGWM\L:S,3SQO/![3 M?FJ@BH>JY\>2I;H_XI^YT*\(6Y$!1FR+>#X)/*=3.;8W:&0%"12HMP_UZP8B MK'B]J6SLOEOV.?7DKSR[?IV@"MR'VR.$AJ"%QJ8&7_119! M]QC4>K.T8FW5+QD;IX,,T&D0.>1#"BOP?WVK3K_)][WA%-,/4$L#!!0 ( M -*(=E@N+\3Y5P< *M+ 5 :6]B="TR,#(S,3(S,5]D968N>&ULU5Q= M;]LV%'T?L/^@><^*_)&D2="T<)RD,)JV09QUW88AH"7:)D*1!DDU#H;]]Y&B M%5LQ*2D?=,>G*/(E>3EO^*Y^ZW? 38/$L[+:[ MN\%?G?91MW.TV_X[^*?_Z=\P5! P(K=CP&$@(1-^W%IK9#%F>(>R:=1MMWM1 M8=C2ED<+CDK6=[W"MA-]^W0QBFL<'AY&^:?2E*,CGI>_ MH#$0N1-K<056"_5?6)B%ZE78Z8:]SLZ")P^XI$TB'II9KV OTA^VE+L8Q? * M3H(ZW1U0[\.J.P0EV J#54EOUT- M2Z1D 40%C&>YFLHB6BL1J;:EDD7SR\?U2AX@(R*B!*71TB8"&+=J\5J<5W!7 M7MO+:>2UO02.?(9$]=,P@1.08?&*X QUOQ)4F@)$W"!=5OTBH'D=80K3,62O MB;)<[TL@SB0:%F=C&#Y0?T6@QMI? I=0T7_5<5-4F(.2O1,1I +;A:RJU A< M"$@2F!3-*#3- T4>T6E.(##>&=*OT<)1)&*6>HA#UZZ$T!T M4\Q"0S*A+ 5+Y' H8,J+BC$80YPW=U-7Y$:ZI=U[L_3&E@!?@_%*O7JPN;D& MVMN0K<_*D&6W*6I>]J GQ>4)H^D3/;=LG3Z!@^Z21S$E0O:R,PR5M>S6<*H> M5I]CRF%RW!(LD^[*N*1"YZHV(/%2ED FES0.I;N 4X#/B$#BOK] MN[UR$J3 MW'4B5$7HJA7ND0(;HMEHF-W>=>AV#>*T--$]\OFZB49ZX,3AMGFW[&V;ZS:= M;,1M]G#O?^?AF_)2QIFGRXNQ5W3UBH#9Y;O/=OD$\'%.*^/A%("Y]CO$@A=O M5@(L7]R,A$RVU" =8,#YE\E(T/C6$F=JRVB&>UY%G>:DS'+M;56N=7#6D6,W MUESV?U"4:NYJLT05?,S:['NHS8^.;\Y$JHM[VUC^7LL::Y:\RB1'O-MQ(X$I M-WW5!6^)@=G7!PY]W9<8$H7C'(.IQ=DE&XVUZYFWS13,[C[<0M>^A S1Y(PD MIW+M*H+*F)O?%2JV;$+(JYS,"7.]-)PB#GRS^*5J=2)X.])G'H MI3I5="R:N$S32Z &\O$+NZ9WU><>&]8Y@3W?EKYU9"QG>RZ3]3(D/6H;2:%- M<^C[OFV95#*QB. R.R_AN:1< /PGFM?.)Z8"NB_YMH78@(]%%J=INL+$(*@0 M8MU$0_5M+!@96)SM,@57%SKQY8R2ZJSCL9F&[%OJ;65A<;S+M'L$XXS)3M#I MCJ^1L%Z$>FRFXZ5O,["5A<7Q+O/L:P;4O>_1?3JFV.+UDHT&Z]O^JYF"Q=\N MT^M"^[-%/ -D"BLV^4RF&KIO,VLE$XL([G/HWR'&'XE<^HX@X#(*)D/.LYH] M#DL9O6WLFRS-*%GT<9\Q?Z58+HH!RS?&F.V8R&BKP?NV"JJF8M'!?9:\/"NY M@G/*A JB @CKJ5U5$4W%MV52(T:6ZYKND^8A$9"!6*#O\!0(L(19LP-H*J*I M^+ES7L/((H[[9#H?P0,@X)36;&B4+/74Z*<49B(6!=Q?&!^E ..3C$O\O#ID ME2PU<#\/\$UX&.1Q66ROKJU148B%6>,43:@UH!ACD7S*A?N!";7U6Y^L5!?6-8=_VV)_ R_*]OVW<3N\3 MD@&L-Q5JII)U4SW*?9T\C$PL(FSC.OIJ(=A(B,?FFH)OT:N6C440ERE[@8FO MKG+!Y.3^"DX@@R2&UW A3F1#MS4*U9;70]^W[?JGT[-HZ#+I?_@>UBGD,4-Y MVQ:Y3*8:NF\;]Y5,+"(4:\VH_&LK^2O5@/HUJ'?_ 5!+ P04 " #2B'98 M1W8#8N@( !T7P %0 &EO8G0M,C R,S$R,S%?;&%B+GAM;,U<6V_CN!E] M+]#_P+HO+3".8V=1-,',+#*Y+(S-7!!GM]L&BP$MT[8PLFA0],1!T?]>7B1; M$OE1FFE)YBF.?#[RZ)QC\2+9KW_<;S+TE; BI?F;P?CD=(!(GM!%FJ_>#'9\ M.?S[X,>W?_S#ZS\-AS^1G##,R0+-G]'U[?0#^NW=_1V:Y@7'>4+0-4UV&Y)S M-$1KSK<7H]'3T]/)8IGF!GDQ_0X_CT8C*^^.'T=_3OR_?_&0XEA2S-O\QQ09"@G!=O!K5.]G.6G5"V M&DU.3\]&%7"@D1?[(FV@G\XJ['CTV_N[6;(F&SQ,R_,X5,EF;'7C\_/SD7I7 M0(OTHE#U=S3!7(G8R0N!"/G?L((-Y:'A>#(\&Y_LB\5 :L!H1N[)$JGN+_CS MEKP9%.EFFTG:ZMB:D:6=0\;82-:/\T599- K$\1-A*5W& M8ON!?)^^Q[I@NHKK(/D^76N5_T^VW&3ZS6(V5,SDZSO1?X,9V7.2+\BBXB8K M'5=.U;"ZXJHF:=)H+).77LK,\RQ$8ZJA@B0G*_IUM""I:'!R)E_(D>9,G:+X MY_,5%8/@Y;S@#">\:DEQ5^U_MF".I]=@PTA!=RPAWW1J6K!FKWANZU4,3@(A M1V>2#W^9#=ZJ]]%CA?C]M6[M0.Z2-=42HVS5DWC9P:Y$C!(J1L8M'S:(+AG= M@.J475+P1$:^K*SF(=-\2=E&#'[\'+1&!#';P;7M]F&+5L.A1H:/Y MWB5W/0)=6H=)@[@:D2DGFZ)_(FHE\5)1Y]TO&;("J9*7% ]#_XZ(&.)[B,FE MZ',A^[TF1<+2K>P7B(<=&B@6 ,]V' XP5,/%BH!+V[KU+F%]6GZ;X567UQH3 MVN22&>RN!$2WM:Z?U<^Z>#[F;BE_OF0$7]$%-,@W(:%F;DU>QL1-O(WD^T@" MHDW;+.(U9FT6Y7QXN&-,)B4M$IS]DV FEN?78J$#^0G"0WD+\S5\UE"DL4B" MD4 C"8_F>H?W:3[C&W[#&&575$0OD?, QQC=IS!P'ISG *9#5.$\245 9EQ\ MOM0QU00ZMH$>92O19_/=)MF2U.V0UUS)ZY?>0[T5Q[I6?Q9\\!29C!WA4:.+ M1B,%CQ\20'%[-@"YO4="#FG] U%#1XE#G6U7&-14XP5%P5 :#H(AL\<8'.X' M.2:< #9P!-I,P0"4EX'8TTRGPC;SK?)ZM+Z8Y@EE8F8C[ZF\>[XG2R+FN@EY M('O^3G3TI2,./>H#1Z3/&4&Q*5"]6-[F/Y2C1]D 4BU$GWWT=LT6L=Z6>8S= M \-YDZYYP3Z+ M]Z-;6]/.:F=-. \6WN1<[HXM%L*#HOPC;U:, 3\=^$#FNABWG=985*)>52^0 MQ*./>33S.U6O)Z%3*:B@42)PX-GIOT:^#.N;ZL*^-Z7U;?HG6G"<_2O=.NY- MN0IB!*#-N2L&&H]$0=0;6=VZ@Z&PBNXM&E=B8L)P-LT79/\S<5\0#&S00)A, M@2R40*202$#CA@!0V/0?D->?]72SH?F,BU7F;(V%:1]W7#YU+A^W=^? 61@V M%.YS@!*BJI J>X5T(:I51@Y,#U\LZ>EABK\HZ;NR>IDJ.I2WC, M;'=)V/A MO*'@E'?/#P5(5T0.C%-]2U2 U0$C0C$ M&DA(!4<:C\J"N %Q*F_FPRF[OWCLC_M=>N?=G0T+/&PP;'RA5.SK.Y$:'3D2 MH-J6/(!2>PO#;9J1#[O-G#!G".JPH.8W^ &F2PS2H+A>FV*:'IM*>O6676%. M5K1C!Z*%#.YPG:7#9(8J7'R?#6'M5ANJ>G/[>(,KE=-3T6VYZ]&Y"=%1&30- M76]V19J3PKV1 MV$*&=;K%$K):PE"%B^RU35B+V395O;G]@/?3A9@4I,M4_W!-C[4_6!,T 3!S M( NB #4K7L0>08<#9D ZY/<6E5]I)A8:F.EEK/O28&"#1L-D"D3B -2["9$O M$(# 9@( =;TY_P\Q_/RZZ"0"EQX]* M-*K!HW[]OEOU>C:Z)?<0C#LJO]*U%B%T3BY,6* 06/BUK5<0I#"1)PV0F'67 M(24]>#LCR8Z)R\UX,G](.?CK2B8LD+<6?FUOU7%$EV@\^ M-W-JZ%U2;V$"N=QF9GR6]?M( V+9:M6O[J=5/!\C+UGAK'S&=9]"2S8#%6K< M-=@9PZY$H')J_BA!T;YT"$C9&';M.GI;EEW3#4[=WR>I($$770=>P!KK40.B M66E3SUQ -:7[9A.7N)@K=KMBN,)XJYTD&2^J(T=+RP.?#[_W<97AHOBX5,^4 M A_<'C4!3._#W/@A) F1\RT%BOBQ[BU[%8[>F@=)2[US\%+@ @?,AY5K5S B M7B:Z-6YG A18L[\3-?J_5/^L^]O_ E!+ P04 " #2B'98]&F[_-\& $ M3P %0 &EO8G0M,C R,S$R,S%?<')E+GAM;-6<76_;-A2&[P?L/VC>M?R9 MMDG0M'"<9#":MH'M==V&(: EVA9"D09)-3:&_?>1HIU8-H^D(&A#7L61#ZGS MGD2W[Y?I23XAKE(&#UK=)KM1H!IQ.*$SL\:F9R%QXWW[W[^Z>TO8?@; MII@CB>-@N@XNKH:?@J_GH^M@2(5$-,+!!8NR%%,9A,%"RN5IJW5_?]^,9PD5 MC&12[4 T(Y:VU/=?S Z#4:_95O^J3]UN^!'Q:!%VV]VCX.].^[3;.3UJ_Q/\ MV__X7QCJ%$A"[Z9(X$"E3,598V%G6[8ZS17(F[H&G!&\ C/@GSWIW*]Q&<-D:1+HM/.MRTXGITU$C:5 MNI2]3M>T_G7 %.4;-%>!NI/?1\-"IJI!PB2.%CDB'='::='2^UYR+!3>7.6U MVE4A";R2F,8XWJ:A>ZB_@QPOBPH]$EU0QHNZ=(="]9B73>"H.6??6C%.6EJK M_I"+S@6K?V[S/?2G0G(4R6U/!$TQR?N_/8BY535O][H;Q=\CI>U9,J0SQM.\ MF!,T?>2WEQT4;A+M6=#T>3%I=59M^U8?#[@4#\!-1&N)N.HOC!8)>4 ZXRRM M*MMFQ^P) C*A$F)+_04BC8#Q&',U$C4")6J&.<5ZW[\CM&L\1 MN:0RD>O^*A$ KKTH(_+HY2A55O\0&"3!SJGK&B>3^05+44(!2+LA1M[QRQ&" MRGT(QIJVG4KOQU*9(3'-.\Q$.$=H:=!@(L5VRR.CS8;;L:HRUH?F@" A/L_& MDD5WP)E5V<:4XY4WYUE]07:^1^[SW54$GHUPL"G ZYNP]C"R M@@8[HC>N(>JKQ&.=_!5!8)RR^I/&%FB$J MSJA"K!'\@O=MSSRU[&+L]$Y5B @1(^5*;:N:T@[B<^''_@Z0L"#@;KSM M-LH_,>+U03Y$YZK?^([Q4 X T3E/99!Q7I!1/J!"X49WVSN,E7H CHYZ+B,\ M3[0=2.4GE$(,;:%F&G'+):O#KU0+P.X'.S-UV0V4>H[(D,9X]0&O2^'MQ1K% M+W2G_FQZD!@ WP\V7NKBNTH(_I2E4\Q+R3V&&9UN&6;UH5ET +R<,U:,@ E: M#6.E/IDE9M6P!CR@C:G "QK8SR)9)0K ZIS!8M0,:<3XDO%<26X>#EBFQI?U M@,7E$V)I2U,-M]RS^HCK20- .V?3;%9JXEA1$)L_NA:=4KR6>*/\Q%.H98( ME,YY.04E _7Q,Y^P^_)%PX/H7/4K_^X]JN0 $)VS=(HZS,!2BZ )S?6^]L^. M*]4"K-0[Y^$41-PP(1'Y*UE6SI6V!N:X]<\,KZ$(H.F>F:.%<(Q*^.V&&'W^ MG7E6#0 CYXP:_9 BN5DP6GZWN!]F=/IGT( Z %[.F3-C'&5<'7"=[G222/ A MP?TP,Q/X=U$"Z@!X.>?&3#C23TZ/U^F4$0!6(<8H]&\%PBX"P.2<";,]SBY7 MT0+1.2[QJVVA1J]_%QNE6@!VCCHM?V!"/E!UPS+&2*CQ/1X*D548:$ ;L]KB M'\UZH@"LCOHJ7QA1MS*(YPXOAU9SK;%&L7_7D^5B 'R.>BF;!5$&UNJ&IA7]/V#Q!&4#94?-G MO,"$U)E#=P/-A8.OMY16)0 U1[V=FVQ*DNB*,%1^][@39XY/7R]W;$( 9*[Z M.2Q-]3-;++H;+U2QQ.=,ZA])T=9_N:M3TM"\:N+?XM03E &4G7-XMI7H4YHA M8ORJBFER-]0,1/Y.C%8MP OWSCDY#^^Z/ER'U^*W'VYT^S?$5NH!.#IG[&R% MB,?G9'%\OA[I'#&-\ 2OY+G:T5T%V,KV9G3R;YWKZ0(!],Y90P]O0E]@$?$D M3QB@; LU>OU;\2K5 K![E@O4VO_ELGRCSDO_S-J[_P%02P$"% ,4 " #2 MB'9831]U.<$8 #!Q@ $ @ $ 9#\8 !D-SDU.#\< !D-SDU.# @ !I;V)T M+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0 ( -*(=EB382[58@$ *@" 5 M " ;0D !I;V)T+3(P,C,Q,C,Q7V-A;"YX;6Q02P$"% ,4 M" #2B'98+B_$^5<' "K2P %0 @ %))@ :6]B="TR,#(S M,3(S,5]D968N>&UL4$L! A0#% @ THAV6$=V V+H" =%\ !4 M ( !TRT &EO8G0M,C R,S$R,S%?;&%B+GAM;%!+ 0(4 Q0 ( M -*(=ECT:;O\WP8 1/ 5 " >XV !I;V)T+3(P,C,Q A,C,Q7W!R92YX;6Q02P4& @ " ' @ #X end XML 21 d795877d10ka_htm.xml IDEA: XBRL DOCUMENT 0001865494 2023-01-01 2023-12-31 0001865494 2023-06-30 0001865494 2024-02-28 iso4217:USD shares true FY 0001865494 DE 10-K/A true 2023-12-31 --12-31 2023 false 001-41008 IO BIOTECH, INC. 87-0909276 Ole Maaløes Vej 3 DK-2200 Copenhagen N DK +45 7070 2980 Common stock, par value $0.001 per share IOBT NASDAQ No No Yes Yes Non-accelerated Filer true true false false false false 31100000 65880914 Portions of the registrant’s proxy statement relating to its 2024 Annual Meeting of Stockholders have been incorporated by reference herein in response to Part III, as specifically set forth in Part III. This Amendment No. 1 on Form 10-K/A (the “Amendment”) of IO Biotech, Inc. (the “Company”) amends the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, originally filed with the Securities and Exchange Commission on March 5, 2024 (the “Original Report”). This Amendment is being filed solely for the purpose of inserting the conformed signature of the current Principal Accounting Officer, which was inadvertently omitted from the Original Report. This Amendment speaks as of the original filing date of the Form 10-K, does not reflect events that may have occurred after the filing date of the Original Report, and does not modify or update in any way the Company’s financial statements or any other disclosures made in the Original Report. No other changes have been made to the Original Report. As required by Rule 12b-15 of the Securities Exchange Act of 1934, as amended, this Amendment contains new certifications by the Company’s principal executive officer and principal financial officer, which are being filed as exhibits to the Amendment. Because the Amendment includes no financial statements, the Company is not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.